Propel Bio Management’s Akero Therapeutics AKRO Stock Holding History

Propel Bio Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-228,884	Closed	-$10.9M	–	21
2025 Q3	$10.9M	Hold	228,884	–	–	10.88%	3
2025 Q2	$12.2M	Hold	228,884	–	–	14.82%	3
2025 Q1	$9.27M	Sell	228,884 -114,845	-33%	-$4.87M	10.76%	3
2024 Q4	$9.56M	Hold	343,729	–	–	9.5%	3
2024 Q3	$9.86M	Buy	343,729 +15,977	+5%	+$417K	5.72%	6
2024 Q2	$7.69M	Hold	327,752	–	–	4.99%	7
2024 Q1	$8.28M	Buy	327,752 +227,700	+228%	+$5.47M	4.82%	7
2023 Q4	$2.34M	Buy	+100,052	New	+$1.97M	1.94%	14

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Propel Bio Management's AKRO Position: Q4 2025 in Review

Propel Bio Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 228,884 shares — an estimated $10.9M sold.

Propel Bio Management first reported a position in AKRO in Q4 2023 and held it in 8 quarters. The position peaked at $12.2M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Propel Bio Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Propel Bio Management sold 228,884 Akero Therapeutics shares in Q4 2025, an estimated $10.9M.
Propel Bio Management first reported a position in Akero Therapeutics in Q4 2023 and held it in 8 quarters.
Propel Bio Management's Akero Therapeutics position peaked at $12.2M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Propel Bio Management's 13F filing for Q4 2025, filed 11 Feb 2026.